Skip to main content
. 2017 Dec 23;9(14):11805–11815. doi: 10.18632/oncotarget.23668

Figure 5.

Figure 5

(A–C) Pooled risk ratio of gefitinib, erlotinib, and afatinib indirectly compared for the ocurrence of diahrrea. EGFR, epidermal growth factor receptor; ORR, overall response rate; PFS, progression-free-survival; OS, overall survival.